Affordable Access

Publisher Website

Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.

Authors
Type
Published Article
Journal
Liver international : official journal of the International Association for the Study of the Liver
Publication Date
Volume
29
Issue
2
Pages
237–241
Identifiers
DOI: 10.1111/j.1478-3231.2008.01859.x
PMID: 18710427
Source
Medline

Abstract

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments